Integrated longitudinal metabolic monitoring before, during and after teplizumab in an adult with stage 2 type 1 diabetes: a case report
4 affiliations
- 1Department of Clinical and Experimental Medicine, University of Catania
- 2Diabetes and Obesity Center, Garibaldi-Nesima Hospital
- 3Department of Medicine and Surgery, “Kore” University of Enna
- 4Internal Medicine, Garibaldi-Nesima Hospital
Abstract
Background: Teplizumab is the first disease-modifying therapy approved to delay progression from stage 2 to stage 3 type 1 diabetes (T1D). Although its efficacy has been demonstrated in randomized clinical trials, the optimal strategy for monitoring the early metabolic response after treatment has not yet been established.
Case presentation: We report the case of a 19-year-old woman diagnosed with stage 2 T1D after severe corticosteroid-associated hyperglycemia unmasked an underlying autoimmune dysglycemic state. The diagnosis was confirmed by progressive deterioration in serial oral glucose tolerance test (OGTT), positivity for multiple islet autoantibodies and preserved endogenous insulin secretion. Following a standard 14-day course of intravenous teplizumab, the patient underwent prospective metabolic evaluation using serial OGTT, mixed-meal tolerance testing (MMTT), continuous glucose monitoring (CGM), pancreatic autoantibodies, screening for extra-pancreatic autoimmunity and safety assessments. Twelve weeks after treatment, OGTT normalized and stimulated C-peptide secretion remained preserved during MMTT, while CGM provided longitudinal characterization of ambulatory glucose profiles throughout the 24-week follow-up, without evidence of progression to stage 3 T1D.
Conclusions: This case illustrates how OGTT, MMTT and CGM can provide complementary information on glucose tolerance, endogenous β-cell function and real-world glycemic homeostasis during early follow-up after teplizumab. Although no conclusions regarding optimal monitoring strategies can be drawn from a single patient, this longitudinal characterization may help inform the design of prospective studies evaluating metabolic monitoring after disease-modifying therapy in stage 2 T1D.
Related
- Fixed-ground multisensor monitoring resolves longitudinal vegetation condition and fuel-state structure in Southern California chaparral and oak scenes
- Association between diabetes mellitus and hearing impairment in the adult Canadian population: data from the Canadian longitudinal study on aging
- Identification of CLOCK and MARK2 as Candidate Blood-Based Biomarkers in Type 2 Diabetes: An Integrated Bulk and Single-Cell Transcriptomic Study
- Predictive consequences of alternative representations of metabolic measurements: A controlled synthetic study of categories, longitudinal information and transition preservation
- Targeting PFKFB3 Metabolic Gatekeeping of β-Cell Dysfunctional States Enables Durable Glucose Tolerance in Type 2 Diabetes
BibTeX
@article{milluzzo2026integrated,
title = {{Integrated longitudinal metabolic monitoring before, during and after teplizumab in an adult with stage 2 type 1 diabetes: a case report}},
author = {Agostino Milluzzo and Teresa Ballirò and Francesco Di Giacomo Barbagallo and Giosiana Bosco and Maurizio Di Marco and Giuseppe Frazzetto and Lucia Frittitta},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1985205},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1985205/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrated longitudinal metabolic monitoring before, during and after teplizumab in an adult with stage 2 type 1 diabetes: a case report
AU - Agostino Milluzzo
AU - Teresa Ballirò
AU - Francesco Di Giacomo Barbagallo
AU - Giosiana Bosco
AU - Maurizio Di Marco
AU - Giuseppe Frazzetto
AU - Lucia Frittitta
PY - 2026
DA - 2026/10/26
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1985205
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1985205/full
AB - Background: Teplizumab is the first disease-modifying therapy approved to delay progression from stage 2 to stage 3 type 1 diabetes (T1D). Although its efficacy has been demonstrated in randomized clinical trials, the optimal strategy for monitoring the early metabolic response after treatment has not yet been established. Case presentation: We report the case of a 19-year-old woman diagnosed with stage 2 T1D after severe corticosteroid-associated hyperglycemia unmasked an underlying autoimmune dysglycemic state. The diagnosis was confirmed by progressive deterioration in serial oral glucose tolerance test (OGTT), positivity for multiple islet autoantibodies and preserved endogenous insulin secretion. Following a standard 14-day course of intravenous teplizumab, the patient underwent prospective metabolic evaluation using serial OGTT, mixed-meal tolerance testing (MMTT), continuous glucose monitoring (CGM), pancreatic autoantibodies, screening for extra-pancreatic autoimmunity and safety assessments. Twelve weeks after treatment, OGTT normalized and stimulated C-peptide secretion remained preserved during MMTT, while CGM provided longitudinal characterization of ambulatory glucose profiles throughout the 24-week follow-up, without evidence of progression to stage 3 T1D. Conclusions: This case illustrates how OGTT, MMTT and CGM can provide complementary information on glucose tolerance, endogenous β-cell function and real-world glycemic homeostasis during early follow-up after teplizumab. Although no conclusions regarding optimal monitoring strategies can be drawn from a single patient, this longitudinal characterization may help inform the design of prospective studies evaluating metabolic monitoring after disease-modifying therapy in stage 2 T1D.
SN - 1664-2392
ER -